Skip to main content
Premium Trial:

Request an Annual Quote

Sun Beats out Compaq, IBM in Bid for Myriad s Computing Needs

Premium

Myriad Genetics has chosen Sun Microsystems to provide the computing infrastructure for its protein-mapping venture with Hitachi and Oracle, according to two sources close to the deal.

Myriad had recently narrowed the field of computing power providers to Sun and Compaq, eliminating IBM, one source said, and would announce Sun as the winner this week. Bill Hockett, a spokesman with Myriad, confirmed that the company had decided upon a vendor, but declined to comment further. A spokesperson from Sun declined to comment.

One source, who asked to remain unidentified, said that Myriad gave the bidders, which included IBM, Compaq, and Sun, less than one month to complete their proposals to provide computing power for analyzing and mining the data from the proteomics project. When Myriad eliminated IBM, the source added, the competition between Compaq and Sun quickly boiled down to price.

Both Compaq and Sun offered significantly discounted bids, the source said, but Sun’s estimated $3 million-$4 million price tag for a high-performance computing platform, typically sold at higher margins, dramatically undercut Compaq’s bid.

— AB and JSM

Filed under

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.